Re7a is a synthetic triple-agonist research peptide with affinity for the GLP-1, GIP and glucagon receptors. It is supplied for in-vitro investigation of multi-receptor metabolic signalling, and is not for human or veterinary use.
Mechanistic focus
- Investigated in multi-receptor signalling pathways (GLP-1, GIP, glucagon)
- Explored in studies involving metabolic system integration
- Studied for its role in complex endocrine signalling models
Research applications
- Multi-receptor signalling research
- Metabolic regulation systems
- Integrated endocrine pathways
Handling & specification
Supplied as a lyophilised powder in a sealed vial, strength as labelled. Store lyophilised material cold and away from light; once reconstituted with bacteriostatic water, keep refrigerated and protected from light. Reconstitution volume is determined by the researcher according to the experimental protocol.
Purity & documentation
Every batch is supplied with batch-specific Certificate of Analysis (COA) documentation where applicable, accessible via the QR code on the vial label or through our COA Verification page. Use the product name and batch/lot number on the vial to locate the relevant records.
Despatched from the UK with tracked delivery.
For research purposes only. Not for human or veterinary use. Sold to qualified researchers and institutions for in-vitro laboratory research only.
